Expert Insight into Emerging Treatments for EGFR TKI-Resistant NSCLC and HER2-Positive NSCLC
February 15, 2023
February 14, 2024
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.
This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
Medical oncologists, thoracic oncologists, pathologists, oncology nurse practitioners, oncology physician assistants, and other HCPs managing patients with NSCLC
Despite substantial advances in the management of non-small cell lung cancer (NSCLC) during the past decade, advanced NSCLC continues to have persistently low 5-year survival rates and imposes a significant burden on patients. Improved molecular-testing practices and integration of new data on targeted treatments could inform treatment decision-making and help clinicians optimize patient care.
Join a panel of experts from the thoracic oncology team to discuss the clinical relevance of HER2 and HER3 status in the treatment of NSCLC. Panelists will explore the identification of actionable mutations in patients with newly diagnosed NSCLC and review how to select appropriate assays for molecular testing. Experts will also look at the landscape of current and emerging targeted therapies and discuss how to account for individual clinical characteristics and mitigate potential adverse effects
After completing this activity, the participant should be better able to:
- Illustrate appropriate testing to identify clinically relevant mutations
- Appraise current and emerging targeted therapies for NSCLC, including mechanisms of action, key trial data, and strategies to manage potential side effects
Lyudmila Bazhenova, MD
Professor of Medicine
Lung Cancer Unit Leader
Director, Hematology and Oncology Training Program
University of California, San Diego
Pasi Janne, MD
Director, Lowe Center for Thoracic Oncology
Director, Belfer Center for Applied Cancer Science
Director, Chen-Huang Center for EGFR Mutant Lung Cancers
Professor of Medicine, Harvard Medical School
Joint Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
|Name of Faculty or Presenter||Reported Financial Relationship|
Lyudmila Bazhenova, MD
Consulting Fee: Janssen, Turning Point, Daichi,
Pasi Janne, MD
Consulting Fee: AstraZeneca; Boehringer
Contracted Research: AstraZenenca; Daiichi
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Inatructions for Participation and Credit
ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”